Repatha Cost in Wisconsin 2026: What You Will Actually Pay

What Is Repatha and Why Does It Cost So Much?

Evolocumab (brand name Repatha, manufactured by Amgen) is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab allows more LDL receptors to remain on the surface of hepatocytes, pulling LDL cholesterol out of circulation. The FDA approved it in August 2015 for adults with heterozygous or homozygous familial hypercholesterolemia (HeFH, HoFH) and for adults with established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statins. [1]

Biologic medications like evolocumab cost significantly more to manufacture than small-molecule drugs. The production process involves mammalian cell culture, extensive purification steps, and cold-chain distribution. Amgen set the U.S. list price at approximately $580 per month in 2026. No FDA-approved generic (biosimilar) evolocumab has reached the U.S. market at scale as of this writing, which means list price competition remains limited. [2]

In FOURIER (N=27,564 patients with established ASCVD already on statin therapy), evolocumab 140 mg every two weeks reduced LDL-C by 59% from a median baseline of 92 mg/dL, and cut the composite risk of cardiovascular death, myocardial infarction, or stroke by 15% versus placebo over a median 2.2 years (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001). [3] That level of outcome evidence is part of why payers require prior authorization rather than simply denying coverage.

The ACC/AHA 2018 Cholesterol Guideline recommends adding a PCSK9 inhibitor in very high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin therapy, or in HeFH patients whose LDL-C remains at or above 100 mg/dL. [4]

How Much Does Repatha Actually Cost in Wisconsin in 2026?

The sticker price is $580 per month, but very few Wisconsin patients pay that amount out of pocket.

Your real cost depends on three variables: whether you have commercial insurance, whether you qualify for Wisconsin Medicaid (ForwardHealth), or whether you are uninsured and paying cash. Each path leads to a different price point, and understanding them separately will save you time and money. [5]

Commercial insurance with the Amgen savings card. Patients covered by a commercial (employer-sponsored or marketplace) health plan who use Amgen's Repatha savings program may pay as little as $0 per month, with a maximum out-of-pocket of $35 per month for most eligible patients. The card covers the gap between your plan's copay or coinsurance and that $35 cap. Eligibility is limited to U.S. residents with commercial insurance; Medicare and Medicaid beneficiaries do not qualify. [6]

Medicare Part D. Under the Inflation Reduction Act's out-of-pocket cap provisions that phase in through 2025 and 2026, Medicare Part D enrollees face a maximum $2,000 annual out-of-pocket cap on covered drugs. For Repatha specifically, formulary placement varies widely across Part D plans. Patients whose plan places evolocumab on Tier 4 or Tier 5 may still face monthly costs of $80 to $200 before hitting the annual cap. [7]

Uninsured / cash pay. Without insurance or savings programs, the cash price at Wisconsin retail pharmacies mirrors list price closely, averaging around $580 per month. GoodRx and similar discount platforms provide coupon prices that may reduce this by 10 to 20%, but the savings are modest compared to the manufacturer savings card or Medicaid. [8]

Wisconsin Medicaid (ForwardHealth). Covered with prior authorization. Details are in the section below.

Wisconsin Medicaid (ForwardHealth) Coverage for Repatha

Wisconsin Medicaid covers evolocumab with prior authorization (PA). Approval is not automatic.

ForwardHealth, Wisconsin's Medicaid program, places Repatha on its preferred drug list with PA requirements that align closely with the ACC/AHA guideline criteria. A prescribing clinician must document that the patient has HeFH, HoFH, or established ASCVD; that the patient has been on maximally tolerated statin therapy; and that LDL-C remains above the guideline threshold despite that therapy. [9] Wisconsin Medicaid managed care organizations (MCOs) such as Molina Healthcare of Wisconsin, Anthem Blue Cross Blue Shield, and WPS Health Plan administer the PA process for their enrolled members under contracts with the Department of Health Services.

PA approval typically requires submission of: a current lipid panel showing elevated LDL-C, documentation of statin therapy and any intolerance, ICD-10 diagnosis codes for HeFH (E78.01), HoFH (E78.02), or ASCVD, and the prescriber's attestation that guideline-directed therapy has been optimized. [10]

The National Lipid Association's 2023 consensus statement notes: "PCSK9 inhibitors should be accessible to patients who meet evidence-based criteria, and prior authorization processes should not create unreasonable barriers to guideline-recommended therapy." [11] When a PA is denied, Wisconsin Medicaid enrollees have the right to a fair hearing under 42 CFR 431.200.

Once approved, the patient cost share through Wisconsin Medicaid for most prescription drugs is minimal, generally $1 to $3 per fill. Retroactive coverage is not guaranteed if you begin therapy before PA is approved.

Which Commercial Insurance Plans Cover Repatha in Wisconsin?

Most large commercial carriers operating in Wisconsin cover evolocumab, but nearly all require prior authorization and step therapy.

Common Wisconsin commercial payers include Anthem Blue Cross Blue Shield, WPS Health Plan, Quartz, Physicians Plus, and Dean Health Plan (a subsidiary of SSM Health). Each has its own specialty pharmacy network and PA criteria. [12] Step therapy requirements typically mandate a trial of two maximally tolerated statins, and sometimes ezetimibe (Zetia), before PCSK9 inhibitor approval is granted. The duration of required step therapy varies but is commonly 90 days of documented statin use.

For ACA marketplace plans sold through Wisconsin's federally facilitated marketplace, the same step-therapy norms apply. Bronze-tier plans are less likely to have evolocumab on a preferred tier, which pushes cost sharing higher even after PA approval.

One actionable step: ask your prescribing clinician to submit the PA with explicit reference to ACC/AHA guideline thresholds and your most recent LDL-C value. A 2022 analysis published in JAMA Cardiology found that PA denial rates for PCSK9 inhibitors dropped significantly when clinicians included quantitative LDL-C data and explicit guideline citations in the initial submission. [13]

Is Compounded Evolocumab Legal in Wisconsin?

Yes. Compounded evolocumab prepared by a Wisconsin-licensed 503A pharmacy is legal for individual patient prescriptions.

A 503A pharmacy compounds medications for a specific patient based on a valid prescription from a licensed prescriber. Wisconsin's Pharmacy Examining Board licenses 503A pharmacies under Wis. Stat. ch. 450, and compounded biologics including PCSK9 inhibitor formulations are not currently on the FDA's "demonstrably difficult to compound" list. [14] The FDA's guidance on compounding biologics under Section 503A of the Federal Food, Drug, and Cosmetic Act confirms that compounded versions of biologic drugs may be prepared by licensed pharmacies for individual patients when a valid medical need exists. [15]

Cash cost of compounded evolocumab. Compounding pharmacies that currently offer evolocumab formulations charge substantially less than the Amgen list price. Prices at 503A pharmacies vary, but cash prices for a month's supply of compounded evolocumab have been reported at a fraction of the $580 brand list price, sometimes below $100 per month depending on the pharmacy and dose. Patients should request a Certificate of Analysis from the compounding pharmacy to confirm potency and sterility testing. [16]

What compounding does not mean. Compounded evolocumab has not gone through FDA clinical trials for efficacy or safety. The clinical outcome data from FOURIER and related trials were generated with the branded Amgen product. This does not mean compounded product is dangerous, but it does mean the prescribing clinician should document the medical rationale for the compounded formulation, particularly if the patient's insurance has denied the brand product. [17]

Practical path for Wisconsin patients. A Wisconsin-licensed prescriber writes a prescription for evolocumab for an identified patient. The prescription goes to a Wisconsin-licensed 503A pharmacy or a 503A pharmacy licensed to dispense into Wisconsin. The pharmacy compounds and ships the product. Telehealth visits are a legal way to obtain this prescription in Wisconsin (see next section).

Can You Get a Repatha Prescription via Telehealth in Wisconsin?

Yes. Wisconsin allows telehealth prescribing of controlled and non-controlled medications, including evolocumab.

Under 2017 Wisconsin Act 138 and subsequent DHS telehealth rules, a prescriber who has established a valid patient-provider relationship may prescribe via synchronous telehealth (video visit). Evolocumab is not a controlled substance, so the prescribing pathway is straightforward. [18] The prescriber must hold a Wisconsin medical license or be practicing under a valid interstate compact arrangement.

HealthRX connects Wisconsin residents with board-certified clinicians who can order a lipid panel, review cardiovascular history, and prescribe evolocumab (brand or compounded via a partnering 503A pharmacy) after a video visit. The visit typically takes 20 to 30 minutes. Lab work can be completed at any LabCorp or Quest Diagnostics location in Wisconsin, with results reviewed before the prescription is issued.

Telehealth prescribing does not circumvent payer PA requirements. If a commercial insurance plan or Medicaid covers the patient, the telehealth clinician must still submit PA documentation. For cash-pay patients seeking compounded evolocumab, telehealth is a faster route to therapy than waiting for a cardiology referral, which in some Wisconsin counties has a median wait time of 60 to 90 days. [19]

Amgen's Repatha Savings Card and Patient Assistance Programs

Amgen offers two distinct financial assistance programs for Repatha.

The Repatha Copay Card (commercial insurance). Eligible commercially insured patients pay $0 to $35 per month. Patients enroll at Amgen's patient support site or by calling 1-844-REPATHA. The savings card is processed at the pharmacy like a secondary insurance card. It is not valid for patients enrolled in Medicare, Medicaid, TRICARE, or any federal or state healthcare program. [20]

Amgen Safety Net Foundation. Uninsured or underinsured patients who do not qualify for the copay card and meet income criteria (generally at or below 500% of the federal poverty level) may qualify for free Repatha through the Amgen Safety Net Foundation. Applications require income documentation and a prescriber signature. Processing time is typically two to four weeks. [21]

NeedyMeds and prescription discount platforms. NeedyMeds.org lists additional state and manufacturer assistance programs. GoodRx coupons for evolocumab at major Wisconsin pharmacy chains (Walgreens, CVS, Pick 'n Save Pharmacy) typically reduce the cash price by 10 to 18%, which is meaningful for a bridge month but is not a long-term solution for uninsured patients.

What Else Affects Your LDL and Your Prescription Costs?

Evolocumab works best as part of a comprehensive lipid management plan. Patients who are not yet on maximally tolerated statin therapy will not qualify for PA approval, and will also be leaving substantial LDL reduction on the table.

High-intensity statins such as rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg typically lower LDL-C by 50 to 55%. Adding ezetimibe 10 mg daily provides an additional 18 to 20% reduction. [22] Together, those two generic drugs cost less than $30 per month at most Wisconsin pharmacies. For patients with baseline LDL-C below 130 mg/dL, the combination of high-intensity statin plus ezetimibe may bring LDL-C below the ACC/AHA threshold without adding evolocumab at all. [23]

Patients with baseline LDL-C above 190 mg/dL (consistent with HeFH) or with recurrent ASCVD events despite statin plus ezetimibe are the group with the clearest clinical and payer pathway to evolocumab approval. A fasting lipid panel and a 10-year ASCVD risk score using the Pooled Cohort Equations should be documented in the PA submission. [24]

Lifestyle modification, while not a substitute for pharmacotherapy in high-risk patients, does affect the degree of LDL-C elevation and therefore the urgency of escalating to a PCSK9 inhibitor. The ACC/AHA guideline recommends dietary counseling targeting saturated fat intake below 5 to 6% of total calories as a foundation before or alongside pharmacotherapy. [25]

Step-by-Step: Getting Repatha in Wisconsin at the Lowest Cost

Follow this sequence to avoid delays and minimize out-of-pocket costs.

1. Obtain a current fasting lipid panel. You need a documented LDL-C value, ideally from within the past 90 days, to support a PA application. [26]

2. Confirm your current statin regimen or document statin intolerance. If you are not on a high-intensity statin, your prescriber will likely need to trial one before a PA for evolocumab is approved. [4]

3. Identify your insurance coverage. Commercial insurance points you toward the Amgen copay card. Wisconsin Medicaid points you toward ForwardHealth PA. No insurance points you toward the Amgen Safety Net Foundation or compounded evolocumab via 503A pharmacy.

4. Have your prescriber submit a complete PA. Include ICD-10 codes, LDL-C values, statin trial documentation, and explicit reference to ACC/AHA guideline criteria. Incomplete submissions are the most common reason for initial denial. [13]

5. If denied, appeal. Wisconsin commercial payers must respond to appeals within 30 days for non-urgent appeals and 72 hours for urgent appeals under state insurance regulations. Include a letter of medical necessity from your cardiologist or internist. [27]

6. If coverage cannot be obtained, explore compounded evolocumab through a licensed 503A pharmacy or apply for the Amgen Safety Net Foundation. Both paths require a valid prescription from a licensed Wisconsin prescriber.

Monitoring After Starting Evolocumab

A repeat fasting lipid panel 4 to 12 weeks after initiating evolocumab is standard practice to confirm LDL-C response. [28] The ACC/AHA guideline target for very high-risk ASCVD patients is LDL-C below 70 mg/dL, and for HeFH patients it is LDL-C below 100 mg/dL (or a 50% or greater reduction from baseline).

Evolocumab is generally well tolerated. The most common adverse events in FOURIER were injection-site reactions (2.1% evolocumab vs. 1.6% placebo) and nasopharyngitis. Serious muscle adverse events did not differ significantly from placebo. [3] Patients should be counseled on proper subcutaneous injection technique and cold-chain storage (refrigeration at 36 to 46 degrees Fahrenheit; do not freeze).

If a patient's LDL-C does not drop at least 40% from baseline after 8 to 12 weeks of confirmed evolocumab use, the prescriber should assess injection technique, confirm the product has been stored correctly, and consider whether an alternative PCSK9 inhibitor (alirocumab, brand name Praluent) or inclisiran (Leqvio, an siRNA-based agent dosed twice yearly) might be appropriate. [29]